Pyxis Oncology, Inc. (PYXS) Stock

Pyxis Oncology, Inc., headquartered in Cambridge, Massachusetts, is a pioneering biopharmaceutical company focused on advancing therapies for the treatment of various cancers. Operating at the forefront of immune-oncology, Pyxis Oncology develops a robust pipeline of innovative product candidates aimed at addressing significant unmet medical needs in oncology.

The company's portfolio includes PYX-106, a promising fully human immunoglobulin G1 isotype siglec-15 targeting antibody under investigation for thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, Pyxis Oncology is developing PYX-102, an immune-therapeutic designed for the treatment of solid tumors, further expanding its therapeutic capabilities in oncology.

Founded in 2018, Pyxis Oncology combines cutting-edge science with strategic innovation to accelerate the development of antibody drug conjugate (ADC) product candidates. These include PYX-201 for NSCLC and breast cancer, PYX-202 targeting small cell lung cancer (SCLC) and soft tissue sarcoma, and PYX-203 for acute myeloid leukemia and myeloid dysplastic syndrome. With a commitment to advancing oncology treatments, Pyxis Oncology continues to push boundaries in cancer therapy research and development.